Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season

Post Date

July 30th 2012

Application Due Date

August 10th 2012

Funding Opportunity Number

CDC-RFA-IP10-0070201SUPP12

CFDA Number(s)

93.185

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

Other

This award will be a continuation of funds intended only for grantee previously awarded under Funding Opportunity Announcement IP10-007, рEffectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Seasonс (U18). A third year of patient enrollment is needed to obtain the sample size necessary to meet the objectives of this study. Despite good enrollment during the second year of the study, 2011-12, few influenza infections were identified. Flu activity was low through the U.S. Also, the number of LRTI hospitalizations was lower than previous years. An additional year would allow a larger sample size. Based on past performance, if current enrollment rates continue and there is 10-15% influenza, sample size will be met.

Funding

• Estimated Total Funding:

  $846000

• Award Range:

  $0 - $0

Grant Description

The purpose of the program is to continue the objectives of FOA IP10-007 to determine the effectiveness of empiric influenza antiviral therapy, in addition to empiric antibiotic therapy, for hospitalized CAP patients, and other patients with lower respiratory tract illness, during the periods when influenza viruses are circulating in the community. This program addresses the рHealthy People 2020с focus area(s) of Immunization and Infectious Diseases.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  Centers for Disease Control and Prevention

• Agency Contact:

  CDC
  Procurement and Grants Office
  TIMS
  Phone 770-488-2700

• Agency Mailing Address:

  PGOTIM@cdc.gov

• Agency Email Address:

  PGOTIM@cdc.gov